Drug intelligence / Profile preview

[68Ga]Ga-DWJ155

Development stage: Phase 1
Lead developer: Novartis
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[68Ga]Ga-DWJ155 is a radiopharmaceutical imaging agent labeled with the positron-emitting isotope gallium-68, under Phase 1 clinical investigation for its effectiveness and safety in imaging adults with advanced breast cancer (both hormone receptor positive, HER2 negative and HER2 positive subtypes) and advanced non-small cell lung cancer (adenocarcinoma subtype)[3]. The agent is used for positron emission tomography (PET) imaging. As its precise molecular target, binding motif, or class has not been detailed in available sources, its exact mechanism remains unspecified beyond general use for tumor PET imaging.

Brand names: [68Ga]Ga-DWJ155
Other names: [68Ga]Ga-DWJ155

Beyond the preview

Go deeper on [68Ga]Ga-DWJ155.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [68Ga]Ga-DWJ155.

Explore the full profile